ORIC Pharmaceuticals
Social media
ORIC Pharmaceuticals Logo
About ORIC Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies to overcome cancer resistance. Its pipeline includes product candidates such as ORIC-114, an inhibitor targeting EGFR and HER2 exon 20 mutations, and ORIC-944, an allosteric inhibitor for prostate cancer. The company also develops ORIC-533 and ORIC-613, targeting mechanisms of resistance in multiple myeloma and breast cancer, respectively. ORIC collaborates with leading pharmaceutical companies to advance its clinical programs. Founded in 2014 and headquartered in South San Francisco, California, ORIC aims to improve outcomes for patients with treatment-resistant cancers.
Address
240 East Grand Avenue, 2nd Floor
South San Francisco, 94080
United States
Year founded
2014
Number of employees
100-200
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
